We are live on ! Find out more
Axa

Axa Portfolio holdings

AUM $91.9M
1-Year Est. Return 27.41%
This Fund
S&P 500
This Quarter Est. Return
+4.28%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$32.9B
AUM Growth
-$855M
Cap. Flow
-$1.68B
Cap. Flow %
-5.1%
Top 10 Hldgs %
29.62%
Holding
1,163
New
73
Increased
397
Reduced
461
Closed
98

Top Buys

Rank Stock Value
1
CRM icon
Salesforce
CRM
+$87.5M
2
SHW icon
Sherwin-Williams
SHW
+$76.1M
3
HD icon
Home Depot
HD
+$68M
4
LIN icon
Linde
LIN
+$55M
5
BMY icon
Bristol-Myers Squibb
BMY
+$50.3M

Top Sells

Rank Stock Value
1
AMD icon
Advanced Micro Devices
AMD
+$95.3M
2
AAPL icon
Apple
AAPL
+$83.2M
3
AVGO icon
Broadcom
AVGO
+$76.2M
4
ELV icon
Elevance Health
ELV
+$71.4M
5
NVDA icon
NVIDIA
NVDA
+$69.2M

Sector Composition

Rank Sector Weight
1 Technology 37.44%
2 Healthcare 14.27%
3 Consumer Discretionary 12.23%
4 Financials 8.85%
5 Industrials 8.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MLKN icon
551
MillerKnoll
MLKN
$1.44B
$4.52M 0.01%
200,269
+83,427
+71% +$2.02M
AGCO icon
552
AGCO
AGCO
$8.67B
$4.46M 0.01%
47,694
+3,876
+9% +$375K
EPAM icon
553
EPAM Systems
EPAM
$6.37B
$4.46M 0.01%
+19,059
New +$4.24M
RNR icon
554
RenaissanceRe
RNR
$13.7B
$4.45M 0.01%
17,905
+336
+2% +$90.2K
HP icon
555
Helmerich & Payne
HP
$4.34B
$4.45M 0.01%
138,821
+1,205
+0.9% +$40.9K
DYN icon
556
Dyne Therapeutics
DYN
$3.34B
$4.44M 0.01%
188,651
-300
-0.2% -$8.87K
TRN icon
557
Trinity Industries
TRN
$2.24B
$4.43M 0.01%
126,152
+68,752
+120% +$2.48M
KYMR icon
558
Kymera Therapeutics
KYMR
$9.41B
$4.39M 0.01%
109,136
-176
-0.2% -$7.95K
TTEK icon
559
Tetra Tech
TTEK
$9.4B
$4.38M 0.01%
110,000
-15,000
-12% -$673K
IDCC icon
560
InterDigital
IDCC
$8.41B
$4.37M 0.01%
22,545
+21,028
+1,386% +$3.68M
ONTO icon
561
Onto Innovation
ONTO
$12B
$4.36M 0.01%
26,187
-2,114
-7% -$386K
WHR icon
562
Whirlpool
WHR
$2.15B
$4.33M 0.01%
37,788
+243
+0.6% +$26.8K
PRGS icon
563
Progress Software
PRGS
$1.79B
$4.3M 0.01%
66,041
-715
-1% -$47.8K
AUTL
564
Autolus Therapeutics
AUTL
$503M
$4.29M 0.01%
+1,824,685
New +$6.17M
NMIH icon
565
NMI Holdings
NMIH
$3.27B
$4.27M 0.01%
116,226
-5,848
-5% -$227K
COP icon
566
ConocoPhillips
COP
$170B
$4.22M 0.01%
42,526
+3,056
+8% +$324K
PPG icon
567
PPG Industries
PPG
$23.3B
$4.21M 0.01%
35,240
+16,949
+93% +$2.12M
LINE
568
Lineage Inc
LINE
$8.76B
$4.17M 0.01%
71,152
-1,748
-2% -$119K
BN icon
569
Brookfield
BN
$82.9B
$4.14M 0.01%
108,086
-19,510
-15% -$735K
TTD icon
570
Trade Desk
TTD
$7.05B
$4.13M 0.01%
35,157
-1,357
-4% -$168K
LAUR icon
571
Laureate Education
LAUR
$4.94B
$4.11M 0.01%
224,667
-2,599
-1% -$45.6K
MXCT icon
572
MaxCyte
MXCT
$123M
$4.11M 0.01%
+986,897
New +$3.73M
WBD icon
573
Warner Bros
WBD
$70.3B
$4.1M 0.01%
387,712
+169,924
+78% +$1.58M
WTS icon
574
Watts Water Technologies
WTS
$11.7B
$4.09M 0.01%
20,142
ENOV icon
575
Enovis
ENOV
$1.03B
$4.08M 0.01%
92,909
+62,784
+208% +$2.76M

Similar funds

Axa's Q4 2024 Portfolio in Review

As of Q4 2024, Axa held 1,163 positions worth $32.9B, down 2.5% from $33.8B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Axa withdrew a net $1.68B in Q4 2024, closing 98 positions and reducing 461 holdings. Its most notable exit was Altair Engineering Inc, an estimated $67.5M position sold in full.

By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 36% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Axa opened a new position in JBT Marel worth $34.4M.

  • Axa's largest Q4 2024 buy was JBT Marel: 270,829 shares worth $34.4M.
  • Axa added most to Salesforce in Q4 2024, an estimated $87.5M increase.
  • Axa's biggest Q4 2024 reduction was Advanced Micro Devices, cutting an estimated $95.3M.
  • Axa fully exited Altair Engineering Inc in Q4 2024, selling an estimated $67.5M.
  • Axa's ten largest holdings make up 30% of its $32.9B portfolio in Q4 2024.
  • Axa opened 73 new positions and closed 98 in Q4 2024.
  • Axa's portfolio value fell 2.5% quarter-over-quarter to $32.9B.

Based on Axa's 13F filing for Q4 2024, filed 14 Feb 2025.